Creative Biolabs performs L. johnsonii-focused isolation and specificity screening from defined sources (e.g., healthy human intestinal samples), followed by phenotypic qualification for colonization-relevant traits. This enables rapid identification of high-performing L. johnsonii candidates and creation of a traceable seed/strain library for downstream studies.
For next-generation approaches, Creative Biolabs supports L. johnsonii strain improvement using modern genetic toolkits (e.g., CRISPR-enabled editing strategies) to enhance acid/bile resilience or to position L. johnsonii as a programmable chassis for controlled expression of research payloads such as antigens, enzymes, or proteins.
We verify L. johnsonii probiotic-relevant mechanisms using targeted functional panels—covering competitive exclusion behaviors, bacteriocin-associated inhibition patterns, and tolerance profiling (including oxidative stress endpoints such as hydrogen peroxide tolerance where appropriate). These MoA screens help convert “strain identity” into actionable, ranked performance.
Creative Biolabs evaluates L. johnsonii adhesion to intestinal epithelial models as a key colonization indicator and quantifies barrier-relevant outcomes (e.g., integrity-supporting phenotypes) using standardized in vitro methods. This module links L. johnsonii surface interaction biology to interpretable, comparative metrics across strains and lots.
L. johnsonii is frequently investigated for immunomodulatory potential. We use controlled cell-based assays to profile cytokine-directional signatures (including anti-inflammatory-associated signals such as IL-10 pathways) and to assess immune polarization tendencies (e.g., Th1/Th2-relevant marker patterns) under standardized stimulation conditions.
Because L. johnsonii can be nutritionally demanding, Creative Biolabs optimizes media composition and fermentation parameters (pH strategy, oxygen control/anaerobiosis, harvest timing) to support high-density growth and high-viability recovery. This module produces development-relevant process knowledge early—before scale becomes a constraint.
We develop protective excipient systems and dosage formats (e.g., lyophilized powder or microencapsulation concepts) to shield L. johnsonii against gastric acid and bile stresses, supporting viable delivery to the intended intestinal environment. Formulation choices are guided by viability retention, release behavior, and manufacturability targets.
To support commercialization feasibility, Creative Biolabs runs accelerated and real-time stability testing for L. johnsonii products under temperature and humidity stress. We quantify viable counts over time and identify key stability drivers—providing data that informs storage conditions, packaging strategy, and shelf-life positioning.
